Press release
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, MOA, ROA by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Crp
The Biliary Tract Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Biliary Tract Cancer Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Biliary Tract Cancer Market.
Some of the key takeaways from the Biliary Tract Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Biliary Tract Cancer treatment therapies with a considerable amount of success over the years.
*
Biliary Tract Cancer companies working in the treatment market are Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others, are developing therapies for the Biliary Tract Cancer treatment
*
Emerging Biliary Tract Cancer therapies in the different phases of clinical trials are- Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others are expected to have a significant impact on the Biliary Tract Cancer market in the coming years.
*
In April 2024, AstraZeneca has released updated exploratory findings from the TOPAZ-1 Phase III clinical trial, showing that Imfinzi (durvalumab), combined with standard-of-care chemotherapy, provided a long-term overall survival (OS) benefit in patients with advanced biliary tract cancer (BTC) at the three-year mark.
*
In December 2023, RenovoRx, a clinical-stage biopharmaceutical company, has chosen Oklahoma University (OU) Health as the initial study center for its Phase III CouGar Trial of RenovoGem for treating bile duct cancer. The trial will evaluate RenovoGem specifically for unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA). This pivotal, randomized trial aims to assess the efficacy and safety of trans-arterial micro-perfusion (TAMP) using the RenovoGem delivery system in combination with gemcitabine and intravenous durvalumab for treating unresectable, locally advanced eCCA.
*
In December 2023, The Scottish Medicines Consortium and the UK's National Institute of Health and Care Excellence (NICE) have endorsed AstraZeneca's durvalumab (Imfinzi) as a first-line treatment for adults with advanced biliary tract cancers in England and Scotland. This immunotherapy should be administered alongside the chemotherapy drugs gemcitabine and cisplatin.
Biliary Tract Cancer Overview
Biliary tract cancer, also known as cholangiocarcinoma, is a type of cancer that arises in the bile ducts, which are the tubes that carry bile (a digestive fluid) from the liver to the gallbladder and small intestine.
Get a Free Sample PDF Report to know more about Biliary Tract Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight [https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Biliary Tract Cancer Drugs Under Different Phases of Clinical Development Include:
*
Keytruda (pembrolizumab): Merck Sharp & Dohme
*
Imfinzi (durvalumab): AstraZeneca
*
Futibatinib (TAS-120): Taiho Oncology
*
Melphalan: Delcath Systems
*
E7090 (tasurgratinib): Eisai
*
TT-00420: TransThera Sciences (Nanjing)
*
ARQ 087 (Derazantinib): Basilea Pharmaceutica
*
Lenvima (lenvatinib): Eisai and Merck & Co
*
Zanidatamab: Zymeworks and BeiGene
*
XmAb20717: Xencor, Inc.
*
Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
*
CTX-009: Compass Therapeutics
*
MEDI5752: AstraZeneca
*
Brigimadlin: Boehringer Ingelheim
*
ZB131: ZielBio, Inc.
*
GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
*
BNT141: BioNTech SE
*
SO-C101: SOTIO Biotech
*
CT-0508: Carisma Therapeutics Inc
*
RAIN-32: Rain Oncology Inc
*
AVA6000: Avacta Life Sciences Ltd
*
DB-1303: DualityBio Inc.
Biliary Tract Cancer Route of Administration
Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Biliary Tract Cancer Molecule Type
Biliary Tract Cancer Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Biliary Tract Cancer Pipeline Therapeutics Assessment
*
Biliary Tract Cancer Assessment by Product Type
*
Biliary Tract Cancer By Stage and Product Type
*
Biliary Tract Cancer Assessment by Route of Administration
*
Biliary Tract Cancer By Stage and Route of Administration
*
Biliary Tract Cancer Assessment by Molecule Type
*
Biliary Tract Cancer by Stage and Molecule Type
DelveInsight's Biliary Tract Cancer Report covers around 80+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Biliary Tract Cancer product details are provided in the report. Download the Biliary Tract Cancer pipeline report to learn more about the emerging Biliary Tract Cancer therapies [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Biliary Tract Cancer Therapeutics Market include:
Key companies developing therapies for Biliary Tract Cancer are - Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others.
Biliary Tract Cancer Pipeline Analysis:
The Biliary Tract Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Biliary Tract Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Biliary Tract Cancer Treatment.
*
Biliary Tract Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Biliary Tract Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Biliary Tract Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Biliary Tract Cancer drugs and therapies [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Biliary Tract Cancer Pipeline Market Strengths
*
The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.
Biliary Tract Cancer Pipeline Market Opportunities
*
Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.
Scope of Biliary Tract Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
*
Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
*
Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
*
Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
Request for Sample PDF Report for Biliary Tract Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Biliary Tract Cancer Report Introduction
2. Biliary Tract Cancer Executive Summary
3. Biliary Tract Cancer Overview
4. Biliary Tract Cancer- Analytical Perspective In-depth Commercial Assessment
5. Biliary Tract Cancer Pipeline Therapeutics
6. Biliary Tract Cancer Late Stage Products (Phase II/III)
7. Biliary Tract Cancer Mid Stage Products (Phase II)
8. Biliary Tract Cancer Early Stage Products (Phase I)
9. Biliary Tract Cancer Preclinical Stage Products
10. Biliary Tract Cancer Therapeutics Assessment
11. Biliary Tract Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Biliary Tract Cancer Key Companies
14. Biliary Tract Cancer Key Products
15. Biliary Tract Cancer Unmet Needs
16 . Biliary Tract Cancer Market Drivers and Barriers
17. Biliary Tract Cancer Future Perspectives and Conclusion
18. Biliary Tract Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=biliary-tract-cancer-pipeline-analysis-2024-fda-approvals-and-emerging-therapies-moa-roa-by-delveinsight-agios-pharma-servier-pharma-merck-sharp-dohme-astrazeneca-taiho-oncology-incyte-crp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, MOA, ROA by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Crp here
News-ID: 3667726 • Views: …
More Releases from ABNewswire
Digital Printing Service Support in Nazareth, PA Expanded by Sign Textile to Cov …
Sign Textile, a full-service digital printing company based in Nazareth, PA, has expanded its production and fulfillment support to businesses across Allentown, Philadelphia, Trenton, and Princeton. The company now offers direct access to custom outdoor signs, banner printing, vehicle wrap services, large format printing, and custom textile products across the broader Pennsylvania and New Jersey region. Orders are available online at signtextile.com.
Digital Printing Service in Nazareth, PA
Digital printing service [https://www.google.com/maps/place/Sign+Textile/@40.7385309,-75.3075722,794m/data=!3m2!1e3!4b1!4m6!3m5!1s0x89c4698e5e06db87:0xec2c645ea7b860f8!8m2!3d40.7385309!4d-75.3075722!16s%2Fg%2F11zk5427c5?hl=en-GB&entry=ttu&g_ep=EgoyMDI2MDIyMy4wIKXMDSoASAFQAw%3D%3D#:~:text=digital%20printing%20service]…
CoreAge Rx Raises the Bar on Medication Delivery With Free 2-Day Shipping, Tempe …
As GLP-1 demand continues to grow across the United States, CoreAge Rx delivers compounded Semaglutide and Tirzepatide directly to patients' doors with speed, discretion, and pharmaceutical-grade handling at no extra cost.
Image: https://www.abnewswire.com/upload/2026/02/97f63fd2a72edd923f925e1750cfbd14.jpg
CoreAge Rx, a LegitScript-certified telehealth weight management provider based in Wichita Falls, Texas, has built a medication delivery model that independent reviewers and patients consistently describe as one of the strongest in the GLP-1 telehealth space. Free 2-day shipping…
CoreAge Rx Builds Its GLP-1 Program Around Patient Support That Goes Beyond the …
With 24/7 access, rapid response times, dedicated care coordinators, and physician continuity throughout treatment, CoreAge Rx has set a new standard for what patient support looks like in telehealth weight management.
Image: https://www.abnewswire.com/upload/2026/02/79b953c7d7b86bdc830623292680666e.jpg
CoreAge Rx, a LegitScript-certified telehealth weight management provider based in Wichita Falls, Texas, has built a patient support model that independent reviewers consistently identify as one of the most comprehensive in the GLP-1 telehealth space. From 24/7 access across…
Healthy for Wellness Has Given an In-Depth Analysis of Why CoreAge Rx Is Better …
Image: https://www.abnewswire.com/upload/2026/02/850d8bbc779e7d12fe40cc6941e07be3.jpg
Healthy for Wellness has published an in-depth analysis [https://healthyforwellness.com/healthy-for-wellness-has-given-an-in-depth-analysis-of-why-coreage-rx-is-better-than-its-competitors/]examining why CoreAge Rx stands out within the growing GLP-1 prescription weight management space. The review evaluates the company's physician-supervised structure, telehealth-based accessibility, compounded GLP-1 medication program, and patient-centered model in comparison to other providers operating in the same category.
CoreAge Rx [https://www.coreagerx.com/] operates as a prescription-based telehealth program that provides compounded GLP-1 medications for eligible adults seeking medically supervised weight management…
More Releases for Biliary
Global Metal Pancreatic Biliary Stent Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Metal Pancreatic Biliary Stent market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The metal pancreatic biliary stent market is witnessing consistent growth due to the rising prevalence of…
Major Market Share Shift in Biliary Catheters Industry: Advancements In Biliary …
What Is the Forecasted Market Size and Growth Rate for the Biliary Catheters Market?
The market size for biliary catheters has experienced robust growth in recent years. There is an expected growth from $3.42 billion in 2024 to $3.75 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 9.7%. Factors like increased occurrences of biliary tract ailments, the popularity of minimally invasive procedures, a growing aging population, more…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Biliary Stents Market - Unleashing Flow: Empowering Biliary Health with Innovati …
Newark, New Castle, USA - new report, titled Biliary Stents Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Biliary Stents market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Biliary Stents market. The report offers an overview of the market, which…
High Prevalence of Biliary Diseases Across the Globe is Driving the Biliary Sten …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.…
Rise in Surgical Procedures of Biliary Diseases is Expected to Boost the Biliary …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.…
